L. Unger

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Defective removal of ribonucleotides from DNA promotes systemic autoimmunity

Claudia Günther, Barbara Kind, Martin A.M. Reijns et al. · Journal of Clinical Investigation · 2014 · 222 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Hans‐Peter Tony, Gerd R Burmester, Hendrik Schulze‐Koops et al. · Arthritis Research & Therapy · 2011 · 208 citations · Full text

Life Sciences, Dermatology, Immunology +16

Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial

Nils Venhoff, Wolfgang Schmidt, Raoul Bergner et al. · The Lancet Rheumatology · 2023 · 89 citations

Life Sciences, Immunology, Pharmacotherapy +12

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)

M. Witt, Mathias Grünke, Fabian Proft et al. · Lupus · 2013 · 87 citations

Life Sciences, Immunology, Internal Medicine +17